Summit Therapeutics Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety coupled to a GTPase KRAS (G12D) targeting moiety through a linker acting as KRAS (G12D) inhibitors and degradation inducers reported to be useful for the treatment of cancer.

Shanghai Jemincare Pharmaceutical Co. Ltd. has synthesized ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.

Beijing Primegene Therapeutics Co. Ltd. has disclosed serine/threonine-protein kinase Nek7 inhibitors reported to be useful for the treatment of cancer, inflammatory bowel disease, stroke, osteoarthritis, multiple sclerosis, rheumatoid arthritis, atherosclerosis and Alzheimer’s disease, among others.

Pliant Therapeutics Inc. has described integrin αvβ1, integrin αvβ6 and/or integrin αvβ8 antagonists reported to be useful for the treatment of cancer and fibrosis.

Ideaya Biosciences Inc. has divulged poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.

CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase cereblon binding moiety coupled to an EGFR-targeting moiety via a linker reported to be useful for the treatment of non-small-cell lung cancer.

Duality Biologics (Suzhou) Co, Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1)-targeting moiety through a linker reported to be useful for the treatment of cancer.

Insilico Medicine Inc. has disclosed E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.

Hepaitech (Beijing) Biopharma Technology Co. Ltd. has described Mas-related G-protein coupled receptor member X4 (MRGPRX4; SNSR5; SNSR6) antagonists reported to be useful for the treatment of anemia, fungal infections, HIV infections, renal disorders, liver diseases, psoriasis, pruritus and urticaria, among others.

Hangzhou Polymed Biopharmaceuticals Inc. has divulged molecular glue degraders comprising cereblon (CRBN) binding agents covalently bound to a zinc finger protein Helios (IKZF2)-targeting moiety acting as IKZF2 degradation and IKZF2/CRBN interaction inducers.